Media, investors, advocacy organizations and others, please contact us here.
For US healthcare professionals only
The purpose of this Travere Therapeutics Medical Affairs website is to support healthcare professionals with scientific information. This website is also a channel for US healthcare professionals to submit questions or connect with Travere Therapeutics US healthcare professionals. The information provided is for educational purposes only and is not intended to promote any products. By continuing to use this site you are acknowledging that you are a US healthcare professional
SING: A Novel Tool for Dietary Management and Monitoring in Clinical Trials of Pegtibatinase, an Investigational Enzyme Replacement Therapy for Classical Homocystinuria
Novel Dietary Management Strategies for Classical Homocystinuria (HCU) in HARMONY/ENSEMBLE Phase 3 Studies of Pegtibatinase, an Investigational Enzyme Replacement Therapy
Latest Results From the COMPOSE® Phase 1/2 Trial for the Treatment of Classical Homocystinuria (HCU) Using Pegtibatinase, a Novel Investigational Enzyme Replacement Therapy
Concomitant Sparsentan and Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Patients With IgA Nephropathy (IgAN) in the PROTECT Open-Label Extension (OLE)
Sparsentan and Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2is) in the PROTECT Open-Label Extension (OLE) Substudy and SPARTACUS: Trials in Progress
The Humanistic Burden of Rare Kidney Diseases: Understanding the Impact of Focal Segmental Glomerulosclerosis (FSGS) and Immunoglobulin A Nephropathy (IgAN) on Patients and Caregivers Study (HONUS): Results for FSGS in the United States (US)